NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer. Trial ID:NCT00567190. Available at: www.clinicaltrials.gov . 247. MINDACT (Microarray In Node-Negative and 1 to 3 positive lymph node disease may avoid chemotherapy): A prospective, randomized study comparing the 70-Gene signature with the common clinical- pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Clinical Trial ID: NCT00433589. Available at: http://clinicaltrials.gov/ct2/show/NCT00433589?term=NCT00433589&ra nk=1 . 248. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20005174 . 249. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). Clinical Trial ID: NCT00310180. Available at: http://clinicaltrials.gov/ct2/show/NCT00310180?term=TAILORx&rank=2 . 250. Swain SM, Wilson JW, Mamounas EP, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-523. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15069113 . 251. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node- positive breast cancer. JAMA 2006;295:1658-1667. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16609087 . 252. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-

2002;347:1999-2009. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12490681 . 240. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11823860 . 241. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655-661. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20204499 . 242. Kunz G. Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients. Arch Gynecol Obstet 2011;283:597-602. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20383789 . 243. Ishitobi M, Goranova TE, Komoike Y, et al. Clinical utility of the 70- gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol 2010;40:508-512. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20110242 . 244. Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010;17:1406-1413. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20094918 . 245. A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/-chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurence score (RS) of 25 or less. RXPONDER: A clinical trial RX for positive node, endocrine responsive breast cancer. Clincial Trial ID NCT01272037. Available at: http://clinicaltrials.gov/show/NCT01272037 . 246. A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of pertuzumab + trastuzumab +

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-84